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Introduction
The development of drug resistance to clinically used anti-
infective agents reveals that there is an urgent need for the 
discovery of new antimicrobial compounds to treat multi-
resistant infections [1]. Considering this, our attention 
focused on thiosemicarbazide and 1,2,4-triazole deriva-
tives, which have been incorporated into a wide range of 
therapeutically interesting molecules and possess many 
medical applications [2].
It is known that thiosemicarbazides act as antibacterial 
[3–5], antifungal [6, 7], antitubercular [8], anticonvulsant 
[9, 10] and antitumor agents [11, 12]. In turn, the 1,2,4-tri-
azoles display a broad range of biological activities, such 
as antibacterial [13–19], antifungal [20–22], antitubercular 
[23–26], antiviral [27] and antiproliferative properties [28–
30]. Several compounds possessing the triazole scaffold are 
clinically useful medicines, such as ribavirin [31], tercona-
zole [32] or fluconazole [33].
Abstract In this paper, we describe twelve 3-hydroxy-
2-naphthoic hydrazide derivatives (six thiosemicarbazides 
and six 1,2,4-triazole-3-thiones) which we have synthe-
sized. Thiosemicarbazide derivatives were prepared by 
condensation reaction of 3-hydroxy-2-naphthoic hydrazide 
with appropriate isothiocyanates. The 1,2,4-triazole-
3-thiones were synthesized by the cyclization reaction of 
corresponding thiosemicarbazide derivatives in alkaline 
media. All obtained compounds have been analyzed by 
1H NMR and 13C NMR spectra and evaluated for in vitro 
antimicrobial activity against a panel of reference strains of 
microorganisms, including Gram-positive bacteria, Gram-
negative bacteria and fungi belonging to yeasts Candida 
spp. Our antimicrobial screening results indicated that 
some of the newly obtained compounds showed high anti-
bacterial activity, especially against Gram-positive bacteria. 
Among them, the activity of compounds 1, 2 and 4 was 
moderate to strong against staphylococci. In addition to 
this, compounds 1 and 2 showed two times higher activity 
than cefuroxime and four times higher activity than ampi-
cillin against Bacillus cereus ATCC 10876.
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Looking for the interesting starting material for new 
research project, our group found 3-hydroxy-2-naph-
thoic hydrazide, which caught our attention. The choice 
of 3-hydroxy-2-naphthoic hydrazide as a starting mate-
rial for our synthesis was based on the literature findings 
concerning this hydrazide. This hydrazide is very useful 
of itself in the histochemical detection of peroxidation in 
animal tissues. According to Pompella and Comporti [34], 
3-hydroxy-2-naphthoic hydrazide/Fast Blue B reaction is 
a sensitive and reliable tool for the revelation of lipid per-
oxidation-derived carbonyl compounds in tissue. Pompella 
and Comporti [34] suggested that in the tissues of hetero-
geneous cell composition its use can allow the approach 
of choice for the recognition of the cell types involved in 
the lipid peroxidation process in vivo. Dogan et al. [35] 
using this hydrazide, synthesized novel thiosemicarbazides, 
1,2,4-triazoles and 1,3,4-thiadiazoles with significant anti-
bacterial activity against Staphylococcus aureus, Escheri‑
chia coli and Pseudomonas aeruginosa, as well as anti-
fungal activity against Candida albicans. Similarly, Khalil 
et al. [36] obtained benzenobenzo[g]phthalazine-1,4-dione 
derivatives from this hydrazide, which showed interesting 
antibacterial activity against Bacillus thuringiensis and 
E. coli, comparable to commonly used chemotherapeu-
tics like ampicillin and chloramphenicol. In another study, 
1,2,4-triazoles derived from this hydrazide showed promis-
ing in vitro anticancer activity against 60 human tumor cell 
lines [37].
As a continuation of our research interest in the field of 
synthesis and antimicrobial screening of heterocyclic com-
pounds, we have undertaken this research, in which we 
have synthesized and test for in vitro antimicrobial activity 
a series of thiosemicarbazides and 1,2,4-triazole-3-thiones 
obtained form 3-hydroxy-2-naphthoic hydrazide. This 
seemed reasonable in the view of the above mentioned facts.
Experimental
Chemistry
All required chemicals and solvents were purchased from 
Sigma-Aldrich (Munich, Germany) and Merck Co. (Darm-
stadt, Germany) and used without further purification. 
Melting points were determined with Fisher–Johns blocks 
(Fisher Scientific, Germany) and are uncorrected. The 1H 
NMR spectra were recorded on a Bruker Avance 300 appa-
ratus (Bruker BioSpin GmbH, Germany) in DMSO-d6 
with TMS as internal standard. The 13C NMR spectra were 
recorded on a Bruker Avance 300 apparatus in DMSO. The 
chemical shifts are expressed on the δ (ppm) scale using 
TMS as the standard reference. The coupling constants (J) 
are given in Hertz. Spin multiples are given as s (singlet), d 
(doublet), dd (doublet of doublets), t (triplet), q (quartet), 
m (multiplet) and b (broad). The progress of the reaction 
and purity of obtained compounds were monitored by TLC, 
using pre-coated aluminum sheets plates 60 F254 (Merck 
Co. USA) in a CHCl3/C2H5OH (10:1, v/v) solvent sys-
tem. The spots were detected by exposure to a UV lamp at 
254 nm. Elemental analyses of obtained compounds were 
carried out with AMZ 851 CHX analyser (PG, Gdan´sk, 
Poland). The results of elemental analyses (C, H, N) were 
within ±0.4 % of the calculated values.
Preparation of thiosemicarbazide derivatives (1–6)
3-Hydroxy-2-naphthoic hydrazide (2.02 g, 10 mmol) was 
added to the flask with 15 ml of ethanol and heated under 
reflux until hydrazide was dissolved. Then 11 mmol of 
appropriate isothiocyanate was added, and the mixture was 
heated under reflux for 3 h. Subsequently, the content of the 
flask was left for 24 h. The obtained precipitate was filtered 
off, dried and crystallized from ethanol.
N‑Ethyl‑2‑[(3‑hydroxynaphthalen‑2‑yl)carbonyl]hydrazi‑
necarbothioamide (1)
CAS Registry Number 219538-16-6. Yield: 95 %; M.p.: 
196–198 °C. Analysis for C14H15N3O2S (289.35) Cal-
culated: C: 58.11 %, H: 5.23 %, N: 14.52 %; Found: C: 
58.22 %, H: 5.26 %, N: 14.49 %. 1H NMR (DMSO-d6) δ 
(ppm) = 1.07–1.11 (t, 3H, CH3), 3.44–3.50 (q, 2H, CH2, 
J = 6 Hz), 7.32–7.39 (m, 2H, ArH), 7.50–7.54 (m, 1H, 
ArH), 7.75–7.78 (d, 2H, ArH, J = 9 Hz), 7.87–7.90 (d, 2H, 
ArH, J = 9 Hz), 8.12–8.14 (m, 1H, ArH), 8.50 (s, 1H, OH), 
9.54 (s, 1H, NH), 10.71 (s, 1H, NH), 11.51 (s, 1H, NH); 
13C NMR (DMSO) δ (ppm) = 14.9 (CH3), 41.1 (CH2), 
111.0, 119.1, 124.3, 126.3, 127.1, 128.9, 129.2, 130.9, 
136.4 (10Car), 154.8 (C=O), 181.3 (C=S).
2‑[(3‑Hydroxynaphthalen‑2‑yl)
carbonyl]‑N‑(prop‑2‑en‑1‑yl)hydrazinecarbothioamide (2)
CAS Registry Number 224456-14-8. Yield: 80 %; M.p.: 
197–199 °C. Analysis for C15H15N3O2S (301.36) Cal-
culated: C: 59.78 %, H: 5.02 %, N: 13.94 %; Found: C: 
59.85 %, H: 5.05 %, N: 13.90 %. 1H NMR (DMSO-d6) δ 
(ppm) = 4.12–4.15 (m, 2H, CH2), 5.05–5.20 (m, 2H, CH2), 
5.79–5.91 (m, 1H, CH), 7.32–7.39 (m, 2H, ArH), 7.49–7.55 
(m, 1H, ArH), 7.75–7.78 (d, 1H, ArH, J = 9 Hz), 7.87–7.90 
(d, 1H, ArH, J = 9 Hz), 8.31–8.34 (m, 1H, ArH), 8.51 (s, 
1H, OH), 9.63 (s, 1H, NH), 10.77 (s, 1H, NH), 11.49 (s, 
1H, NH); 13C NMR (DMSO) δ (ppm) = 31.2 (CH2), 46.4 
(CH2), 111.0, 115.8, 119.0, 124.3126.3, 127.1, 128.9, 
129.2, 130.9, 135.3, 136.5 (10Car), 132.6 (CH), 165.1 
(C=O), 183.9 (C=S).




Yield: 94 %; M.p.: 196–197 °C. Analysis for C19H17N3O3S 
(367.42) Calculated: C: 62.11 %, H: 4.66 %, N: 11.44 %; 
Found: C: 62.15 %, H: 4.63 %, N: 11.47 %. 1H NMR 
(DMSO-d6) δ (ppm) = 3.83 (s, 3H, CH3), 6.92–6.97 (m, 
1H, ArH), 7.05–7.07 (m, 1H, ArH), 7.14–7.19 (m, 1H, 
ArH), 7.32 (s, 1H, OH), 7.34–7.39 (m, 1H, ArH), 7.50–7.55 
(m, 1H, ArH), 7.76–7.78 (d, 1H, ArH, J = 6 Hz), 7.93–7.94 
(m, 1H, ArH), 8.08–8.09 (m, 1H, ArH), 8.47–8.48 (m, 1H, 
ArH), 8.63–8.64 (m, 1H, ArH), 9.48 (s, 1H, NH), 11.20 
(s, 1H, NH), 11.71 (s, 1H, NH); 13C NMR (DMSO) δ 
(ppm) = 56.18 (CH3), 111.8, 113.3, 120.3, 121.6, 122.5, 
124.3, 126.3, 128.8, 130.2, 132.5, 136.3, 150.1, 155.2 
(16Car), 165.1 (C=O), 180.8 (C=S).
2‑[(3‑Hydroxynaphthalen‑2‑yl)carbonyl]‑N‑(3‑methoxy‑
phenyl)hydrazinecarbothioamide (4)
Yield: 93 %; M.p.: 198–200 °C. Analysis for C19H17N3O3S 
(367.42) Calculated: C: 62.11 %, H: 4.66 %, N: 11.44 %; 
Found: C: 62.18 %, H: 4.62 %, N: 11.41 %. 1H NMR 
(DMSO-d6) δ (ppm) = 3.75 (s, 3H, CH3), 6.73–6.77 (m, 
2H, ArH), 7.06–7.09 (d, 1H, ArH, J = 9 Hz), 7.23–7.28 
(m, 2H, ArH), 7.33 (s, 1H, OH), 7.34–7.39 (m, 2H, 
ArH), 7.49–7.55 (m, 1H, ArH), 7.76–7.79 (d, 1H, ArH, 
J = 9 Hz), 7.90–7.93 (m, 1H, ArH), 8.53 (s, 1H, NH), 
9.86 (s, 1H, NH), 11.56 (s, 1H, NH); 13C NMR (DMSO) 
δ (ppm) = 55.56 (CH3), 110.9, 124.4, 121.6, 126.3, 128.9, 




CAS Registry Number 224456-22-8. Yield: 86 %; M.p.: 
194–196 °C. Analysis for C19H17N3O3S (367.42) Cal-
culated: C: 62.11 %, H: 4.66 %, N: 11.44 %; Found: 
C: 62.15 %, H: 4.63 %, N: 11.48 %. 1H NMR (DMSO-
d6) δ (ppm) = 3.75 (s, 3H, CH3), 6.90–6.93 (d, 2H, ArH, 
J = 9 Hz), 7.27–7.36 (m, 3H, ArH), 7.37 (s, 1H, OH), 
7.47–7.54 (m, 1H, ArH), 7.75–7.78 (d, 2H, ArH, J = 9 Hz), 
7.81–7.92 (m, 2H, ArH), 8.53 (s, 1H, NH), 9.76 (s, 1H, 
NH), 11.54 (s, 1H, NH); 13C NMR (DMSO) δ (ppm) = 55.7 
(CH3), 110.9, 113.8, 119.3, 124.3, 126.3, 127.2, 128.9, 
129.3, 132.3, 136.4 (16Car), 157.2 (C=O), 179.4 (C=S).
N‑(4‑Ethoxyphenyl)‑2‑[(3‑hydroxynaphthalen‑2‑yl)car‑
bonyl]hydrazinecarbothioamide (6)
Yield: 94 %; M.p.: 195–197 °C. Analysis for 
C20H19N3O3S (381.45) Calculated: C: 62.97 %, H: 
5.02 %, N: 11.02 %; Found: C: 62.91 %, H: 5.06 %, N: 
11.05 %. 1H NMR (DMSO-d6) δ (ppm) = 1.28–1.32 (t, 
3H, CH3, J = 6 Hz), 3.93–4.00 (q, 2H, CH2, J = 6 Hz), 
6.83–6.86 (d, 2H, ArH, J = 9 Hz), 7.33–7.36 (d, 2H, ArH, 
J = 9 Hz), 7.38–7.39 (m, 2H, ArH), 7.50–7.55 (m, 1H, 
ArH), 7.76–7.79 (d, 1H, ArH, J = 9 Hz), 7.88–7.91 (d, 
1H, ArH, J = 9 Hz), 8.39 (s, 1H, ArH), 8.52 (s, 1H, OH), 
8.76 (s, 1H, NH), 10.55 (s, 1H, NH), 11.51 (s, 1H, NH); 
13C NMR (DMSO) δ (ppm) = 15.1 (CH3), 63.7 (CH2), 
109.6, 114.5, 117.0, 124.0, 126.3, 127.2, 127.3, 128.1, 




A mixture of appropriate thiosemicarbazide 1–6 (10 mmol) 
and 20–40 ml of 2 % aqueous solution of sodium hydrox-
ide was refluxed for 2 h. Then, the solution was neutralized 
with diluted hydrochloric acid, and the formed precipitate 
was filtered off and crystallized from ethanol.
4‑Ethyl‑5‑(3‑hydroxynaphthalen‑2‑yl)‑2,4‑di‑ 
hydro‑3H‑1,2,4‑triazole‑3‑thione (7)
CAS Registry Number 219538-20-2. Yield: 92 %; M.p.: 
223–225 °C. Analysis for C14H13N3OS (271.34) Calcu-
lated: C: 61.97 %, H: 4.83 %, N: 15.49 %; Found: C: 
61.92 %, H: 4.87 %, N: 15.53 %. 1H NMR (DMSO-d6) δ 
(ppm) = 1.03–1.07 (t, 3H, CH3, J = 6 Hz), 3.86–3.94 (q, 
2H, CH2, J = 9 Hz), 7.34–7.39 (m, 2H, ArH), 7.49–7.54 
(m, 1H, ArH), 7.79–7.81 (d, 2H, ArH, J = 6 Hz), 7.88–
7.90 (d, 2H, ArH, J = 6 Hz), 8.03 (s, 1H, ArH), 10.65 
(s, 1H, OH), 13.93 (s, 1H, NH); 13C NMR (DMSO) δ 
(ppm) = 13.7 (CH3), 45.2 (CH2), 110.1, 116.7, 124.2, 




CAS Registry Number 29213-07-8 Yield: 92 %; M.p.: 
199–200 °C. Analysis for C15H13N3OS (283.30) Calcu-
lated: C: 63.58 %, H: 4.62 %, N: 14.83 %; Found: C: 
63.52 %, H: 4.65 %, N: 14.79 %. 1H NMR (DMSO-d6) δ 
(ppm) = 4.61–4.62 (d, 2H, CH2, J = 3 Hz), 4.69–4.95 (dd, 
2H, CH2, J = 9 Hz), 5.59–5.71 (m, 1H, CH), 7.32–7.37 
(m, 2H, ArH), 7.47–7.53 (m, 1H, ArH), 7.77–7.80 (d, 1H, 
ArH, J = 9 Hz), 7.86–7.88 (d, 2H, ArH, J = 6 Hz), 7.98 (s, 
1H, ArH), 10.68 (s, 1H, OH), 14.01 (s, 1H, NH); 13C NMR 
(DMSO) δ (ppm) = 46.18 (CH2), 110.1, 116.6, 124.2, 
126.5, 127.5, 128.3, 128.7, 131.9, 136.0, 150.3 (10Car) 
117.6 (= CH2), 132.6 (CH), 167.4 (C=S).




Yield: 93 %; M.p.: 220–222 °C. Analysis for C19H15N3O2S 
(349.41) Calculated: C: 65.31 %, H: 4.33 %, N: 12.03 %; 
Found: C: 65.38 %, H: 4.31 %, N: 12.06 %. 1H NMR 
(DMSO-d6) δ (ppm) = 3.54 (s, 3H, CH3), 6.92–6.99 (m, 
2H, ArH), 7.05 (s, 1H, ArH), 7.25–7.35 (m, 3H, ArH), 
7.39–7.45 (m, 1H, ArH), 7.62–7.65 (d, 2H, ArH, J = 9 Hz), 
7.79–7.81 (d, 2H, ArH, J = 6 Hz), 7.87 (s, 1H, ArH), 
10.19 (s, 1H, OH), 14.00 (s, 1H, NH); 13C NMR (DMSO) 
δ (ppm) = 55.9 (CH3), 109.4, 112.8, 116.8, 120.5, 123.0, 
123.9, 126.2, 127.0, 128.0, 128.5, 130.8, 131.3, 132.3, 
135.7, 150.8, 153.5 (16Car), 168.7 (C=S).
5‑(3‑Hydroxynaphthalen‑2‑yl)‑4‑(3‑methoxyphenyl)‑2,4‑di‑
hydro‑3H‑1,2,4‑triazole‑3‑thione (10)
Yield: 94 %; M.p.: 271–273 °C. Analysis for C19H15N3O2S 
(349.41) Calculated: C: 65.31 %, H: 4.33 %, N: 12.03 %; 
Found: C: 65.37 %, H: 4.37 %, N: 12.00 %. 1H NMR 
(DMSO-d6) δ (ppm) = 3.56 (s, 3H, CH3), 6.82–6.95 (m, 
3H, ArH), 7.09 (s, 1H, ArH), 7.20–7.33 (m, 2H, ArH), 
7.42–7.47 (m, 1H, ArH), 7.66–7.68 (d, 1H, ArH, J = 6 Hz), 
7.78–7.81 (d, 1H, ArH, J = 9 Hz), 8.03 (s, 1H, ArH), 10.30 
(s, 1H, OH), 14.15 (s, 1H, NH); 13C NMR (DMSO) δ 
(ppm) = 55.65 (CH3), 109.6, 114.5, 116.9, 120.4, 124.0, 
126.4, 127.2, 128.1, 128.6, 129.8, 132.7, 135.7, 135.9, 
150.0, 153.5, 159.3 (16Car), 169.1 (C=S).
5‑(3‑Hydroxynaphthalen‑2‑yl)‑4‑(4‑methoxyphenyl)‑2,4‑di‑
hydro‑3H‑1,2,4‑triazole‑3‑thione (11)
CAS Registry Number 910875-05-7. Yield: 95 %; M.p.: 
272–274 °C. Analysis for C19H15N3O2S (349.41) Cal-
culated: C: 65.31 %, H: 4.33 %, N: 12.03 %; Found: C: 
65.37 %, H: 4.31 %, N: 12.07 %. 1H NMR (DMSO-d6) 
δ (ppm) = 3.68 (s, 3H, CH3), 6.85–6.88 (d, 2H, ArH, 
J = 9 Hz), 7.08 (s, 1H, ArH), 7.19–7.22 (d, 2H, ArH, 
J = 9 Hz), 7.28–7.33 (m, 1H, ArH), 7.41–7.46 (m, 1H, 
ArH), 7.65–7.68 (d, 1H, ArH, J = 9 Hz), 7.79–7.81 (d, 
1H, ArH, J = 6 Hz), 8.02 (s, 1H, ArH), 10.27 (s, 1H, OH), 
14.09 (s, 1H, NH); 13C NMR (DMSO) δ (ppm) = 55.7 
(CH3), 109.6, 114.2, 116.9, 124.0, 126.3, 127.2, 127.4, 




Yield: 94 %; M.p.: 274–276 °C. Analysis for C20H17N3O2S 
(363.43) Calculated: C: 66.10 %, H: 4.71 %, N: 11.56 %; 
Found: C: 66.15 %, H: 4.70 %, N: 11.59 %. 1H NMR 
(DMSO-d6) δ (ppm) = 1.23–1.29 (t, 3H, CH3, J = 9 Hz), 
3.90–3.97 (q, 2H, CH2, J = 6 Hz, J = 9 Hz), 6.83–6.86 (d, 
2H, ArH, J = 9 Hz), 7.07 (s, 1H, ArH), 7.17–7.20 (d, 2H, 
ArH, J = 9 Hz), 7.28–7.33 (m, 1H, ArH), 7.41–7.47 (m, 
1H, ArH), 7.65–7.68 (d, 1H, ArH, J = 9 Hz), 7.79–7.81 (d, 
1H, ArH, J = 6 Hz), 8.02 (s, 1H, ArH), 14.08 (s, 1H, NH); 
13C NMR (DMSO) δ (ppm) = 15.0 (CH3), 63.7 (CH2), 
109.6, 114.5, 117.0, 124.0, 126.3, 127.2, 127.3, 128.1, 
128.6, 129.6, 132.7, 135.8, 150.3, 153.3, 153.4, 158.8 
(16Car), 168.4 (C=S).
Microbiology
In vitro antimicrobial assay
The examined compounds 1–12 were screened in vitro for 
antibacterial and antifungal activity. Procedure for antimi-
crobial assay is presented in Supplemental Material.
Results and discussion
Chemistry
The main purpose of this work was the synthesis, spectral 
identification and in vitro antimicrobial screening of thio-
semicarbazide (1–6) and 1,2,4-triazole-3-thione derivatives 
(7–12). The compounds 1–12 were synthesized according 
to the steps presented in Scheme 1. Compounds 3, 4, 6, 9, 
10 and 12 are unknown in scientific literature.
1,2,4-Triazole derivatives (7–12) were prepared in two-
step synthesis. In the first step of synthesis, 3-hydroxy-
2-naphthoic hydrazide was subjected to condensation 
reaction with appropriate isothiocyanates to afford 1,4-dis-
ubstituted thiosemicarbazide derivatives (1–6). Then new 
1,2,4-triazole-3-thiones (7–12) were synthesized by the 
cyclization reaction of corresponding thiosemicarbazide 
(1–6) derivatives in alkaline media.
All synthesized compounds are stable solids and dis-
solve in DMSO in room temperature. The spectral data 
(1H NMR, 13C NMR) confirm the successful synthesis of 
desired compounds (7–12).
In the 1H NMR spectra of 1,4-disubstituted thiosemi-
carbazides (1–6), three typical proton singlet signals for 
the three NH groups were observed in the range of δ 8.53–
11.71 ppm. Whereas in the 13C NMR two signals for C=O 
group and C=S group were observed at δ 154.8–165.1 ppm 
and δ 168.4–183.0 ppm, respectively. The 1,2,4-triazole-
3-thiones (7–12) in 1H NMR spectra showed characteristic 
singlet signal for NH group at δ 13.93–14.15 ppm. Beside 
this, in 13C NMR spectra for these compounds (7–12) a sig-
nal for C=S was observed at δ 166.7–169.1 ppm. All other 
aliphatic and aromatic signals were found at usual regions. 
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The above mentioned spectral data successfully confirmed 
the formation of expected products.
The synthesized compounds (1–12) were screened 
in vitro for antibacterial and antifungal activity.
Microbiology
The results of our study indicated that examined com-
pounds 1–3, 5, 6, 9–12 had no inhibitory effect on the 
growth of reference strains of Gram-negative bacteria, i.e., 
E. coli ATCC 25922, Klebsiella pneumoniae ATCC 13883, 
Proteus mirabilis ATCC 12453, Salmonella typhimurium 
ATCC 14028 and P. aeruginosa ATCC 9027. Moreover, 
compounds 6, 10 and 12 had no activity against the other 
reference strains of bacteria (Table 1).
On the basis of minimal inhibitory concentration (MIC) 
values presented in Table 1, obtained by the broth microdi-
lution method, it was shown that some of the tested com-
pounds showed high influence on the growth of Gram-pos-
itive bacteria.
Among them, compounds 1, 2 and 4 possessed the highest 


































Scheme 1  Synthesis scheme of 1,2,4-triazole derivatives (7–12)
Table 1  Activity data expressed as MIC [µg/ml] against the reference strains of bacteria and fungi
The standard compounds used as positive controls: ciprofloxacin (CPX), cefuroxime (CFX), ampicillin (APC) for bacteria and fluconazole 
(FLU*) for fungi
Compounds with bactericidal effect (MBC/MIC ≤ 4) are marked with bold
“–” no activity, nd not determined, MIC minimal inhibitory concentration, MBC minimal bactericidal concentration
Species/compound MIC (MBC/MFC) [µg/ml] of the tested compounds CPX CFX APC FLU
1 2 3 4 5 7 8 9 11
Gram-positive bacteria
 Staphylococcus aureus ATCC 25923 15.62 15.62 – 15.62 – 62.5 62.5 125 250 0.488 0.49 nd nd
 Staphylococcus aureus ATCC 6538 31.25 31.25 – 15.62 – 125 125 62.5 250 0.244 0.98 nd nd
 Staphylococcus aureus ATCC 43300 15.62 7.81 250 7.81 – 62.5 125 31.25 250 0.244 nd nd nd
 Staphylococcus epidermidis ATCC 12228 7.81 3.91 – 15.62 – 62.5 125 62.5 250 0.122 0.24 nd nd
 Micrococcus luteus ATCC 10240 62.5 250 – 31.25 1000 125 125 31.25 125 0.976 0.98 nd nd
 Bacillus subtilis ATCC 6633 31.25 15.62 – 31.25 – 125 125 62.5 250 0.031 15.62 nd nd
 Bacillus cereus ATCC 10876 15.62 15.62 – 1000 – 125 125 62.5 250 0.061 31.25 62.5 nd
Gram-negative bacteria
 Bordetella bronchiseptica ATCC 4617 – – – 250 – 500 500 – – 0.976 nd nd nd
Fungi
 Candida albicans ATCC 2091 – – – 1000 – 500 500 1000 – nd nd nd 0.244
 Candida albicans ATCC 10231 1000 – – 1000 – 500 500 – – nd nd nd 0.976
 Candida parapsilosis ATCC 22019 1000 – – – – 500 500 1000 – nd nd nd 1.953
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ml. S. epidermidis ATCC 12228 and S. aureus ATCC 43300 
were especially sensitive to them.
Compound 1 showed highest activity toward S. epider‑
midis ATCC 12228 (MIC = 7.81 µg/ml) and S. aureus ATCC 
43300 (MIC = 15.62 µg/ml) with bactericidal effect. The 
activity against other Staphylococcus species was strong 
(MIC = 15.62–31.25 µg/ml). Compound 2 showed the high-
est activity of all synthesized compounds against S. epider‑
midis ATCC 12228 (MIC = 3.91 µg/ml) but with bacte-
riostatic effect. The activity against S. aureus ATCC 43300 
was also very strong (MIC = 7.81 µg/ml) or strong against 
S. aureus ATCC 25923 and S. aureus ATCC 6538 with 
MIC = 15.62 µg/ml and 31.25 µg/ml, respectively. Com-
pound 4 showed the strongest activity with bactericidal effect 
against S. aureus ATCC 43300. Its activity against other 
staphylococci was also very good (MIC = 15.62 µg/ml).
The growth of Micrococcus luteus ATCC 10240 was 
inhibited strongly by compounds 4 and 9 (MIC = 31.25 µg/
ml) with bacteriostatic effect. The MIC values of other 
compounds were much higher for this microorganism 
(MIC = 62.5–125 µg/ml), with bacteriostatic or bacteri-
cidal effect.
Considering Bacillus subtilis ATCC 6633, the highest 
antibacterial activity against this microorganism was shown 
by compound 2 (MIC = 15.62 µg/ml) with bacteriostatic 
effect. The activity of this compound was equal to the 
activity of cefuroxime (MIC = 15.62 µg/ml). Compounds 
1 and 4 showed also high activity against this bacterium 
(MIC = 31.25 µg/ml) with bacteriostatic and bactericidal 
effect, respectively.
It is worth to underline that compounds 1 and 2 
showed two times higher activity than cefuroxime 
(MIC = 31.25 µg/ml) against Bacillus cereus ATCC 
10876. The activity of these compounds (MIC = 15.62 µg/
ml) was also 4 times higher than the activity of ampicillin 
(MIC = 62.5 µg/ml) against this pathogen. The sensitive-
ness of B. cereus to synthesized compounds is very impor-
tant due to the fact that this pathogen is a common source 
of severe infections [38].
The activity of compounds 7–9 against Gram-positive 
bacteria was good with MIC = 62.5–125 µg/ml, and had 
bactericidal or bacteriostatic effect (MBC/MIC = 1–32). 
In turn, the minimum concentrations of 11, which inhib-
ited the growth of these microorganisms were lower 
(MIC = 125–250 µg/ml).
Besides, compounds 4, 7 and 8 were found to exhibit 
some activity against B. bronchiseptica ATCC 4617, 
belonging to Gram-negative bacteria (MIC = 250–500 µg/
ml). Compounds 7 and 8 had bactericidal effect against this 
microorganism.
The obtained compounds indicated also some activ-
ity against Candida spp. ATCC, belonging to yeasts. 
The substances 7 and 8 exhibited moderate activity 
(MIC = 500 µg/ml) with fungicidal effect. The other sub-
stances had mild or no activity toward yeasts (Table 1).
Structure–activity relationship
On the basis of our antimicrobial assay results, we can con-
clude that the introduction of 3-methoxyphenyl substituent 
in 1,2,4-triazole derivative (10) can be connected with the 
disappearance of the activity of this compound, whereas the 
same substituent in thiosemicarbazide (4) did not revealed 
such attribute and was active against many bacterial strains.
The thiosemicarbazide derivatives 1 and 2 substituted 
with aliphatic substituents: ethyl (1) and allyl (2) as well as 
compound 4 substituted with meta-methoxyphenyl showed 
the strongest activity among all of synthesized compounds. 
Ortho-methoxyphenyl and para-methoxyphenyl thiosemi-
carbazide derivatives (3, 5) showed the weakest activity 
among all thiosemicarbazide derivatives. In the case of 
thiosemicarbazide (6) and 1,2,4-triazole derivative (12), the 
presence of 4-ethoxyphenyl substituent can be connected 
with the lack of antimicrobial activity. The 1,2,4-triazole 
derivative 9, which is substituted with ortho-methoxyphe-
nyl substituent in comparison to the thiosemicarbazide with 
the same substituent (3), showed moderate to good activity 
against bacterial strains.
In general, the introduction of alkyl (1, 2) and 3-meth-
oxyphenyl substituents (4) was the most beneficial in terms 
of bioactivity in the case of thiosemicarbazides, whereas in 
1,2,4-triazoles the compounds with alkyl (7, 8), 2-methoxy-
phenyl (9), 4-methoxyphenyl (11) substituents displayed 
the most significant activity.
Conclusions
In this work, we synthesized and analyzed 6 thiosemicar-
bazide derivatives (1–6) and 6 1,2,4-triazole derivatives 
(7–12) and tested them against a panel of bacterial and fun-
gal strains. Our antimicrobial screening results indicate that 
some of the newly obtained compounds showed significant 
antibacterial activity, especially against Gram-positive bac-
teria. Among them, the activities of compounds 1, 2 and 4 
were moderate to strong against staphylococci. In addition 
to these compounds 1 and 2 showed two times higher activ-
ity than cefuroxime and 4 times higher activity than ampi-
cillin against B. cereus ATCC 10876.
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